SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Synthesis in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 6 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Prostate cancer metastasis and health disparities: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Pooled it
- Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.JAMA network open · 2021Pooled it
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- Trial
- Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO clinical cancer informatics · 2025Trial
- Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab.The oncologist · 2023Trial
- Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.JAMA oncology · 2019Trial
- Healthcare System Drivers of Prostate Cancer Disparities: Real-World Evidence, Informatics Pathways, and Policy Translation.Healthcare (Basel, Switzerland) · 2026Article
- Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).The journal of liquid biopsy · 2026Article
- Icariin suppresses glycolysis in prostate cancer by upregulating ALKBH5 to mediate EARS2 mJournal of molecular histology · 2026Article
- Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.JNCI cancer spectrum · 2026Article
- Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (medRxiv : the preprint server for health sciences · 2026Article
- Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.The oncologist · 2026Article
- Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer.NPJ precision oncology · 2025Article
- Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis.Journal of translational medicine · 2025Article
- Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.Prostate cancer and prostatic diseases · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 5 countries.
Funding
Abstract
purposeSeveral studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen.
methodsIndividual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases).
resultsOf 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men ( P < .001).
conclusionWhen adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.